Growth Hormone Secretion
Hulk Stack
Hulk blend; IGF-1 LR3 + CJC-1295 + Ipamorelin; anabolic GH/IGF stack
GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog
This Hulk Stack entry draws on 4 cited sources published 1996 to 2006. The evidence available is graded Anecdotal on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog
- Drug class
- Growth Hormone Secretion
- Structure
- Three-vial protocol rather than a single co-formulated vial: CJC-1295 (29-aa GHRH analog), Ipamorelin (pentapeptide), IGF-1 LR3 (70-aa engineered IGF-1 with Arg3 substitution and N-terminal extension)
- Route
- SC injection (typically 2-3 separate sites)
- Half-life
- CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs
- Evidence tier
- Anecdotal
- Availability
- Compounding Restricted
Mechanism of action
Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation.
Reported areas of research
Muscle accrual and recovery support through layered GH + IGF action; reported effects include improved recovery and lean-mass gain during dosing cycles
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved
Compared with
Hulk Stack has published head-to-head comparisons with 14 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
- Hulk Stack vs CJC-1295
- Hulk Stack vs CJC-1295 + Ipamorelin
- Hulk Stack vs GHRP-2
- Hulk Stack vs GHRP-6
- Hulk Stack vs Hexarelin
- Hulk Stack vs IGF-1 DES
- Hulk Stack vs IGF-1 LR3
- Hulk Stack vs Ipamorelin
- Hulk Stack vs MGF
- Hulk Stack vs MK-677
- Hulk Stack vs PEG-MGF
- Hulk Stack vs Sermorelin
- Hulk Stack vs Tesamorelin
- Hulk Stack vs Tesamorelin + Ipamorelin
Frequently asked questions
What dosing is reported for Hulk Stack in research literature?
Published peptide research reports the following dosing approach for Hulk Stack: Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks. This is a research reference, not a clinical recommendation.
How is Hulk Stack administered in research?
Hulk Stack is administered via the following routes in published studies: SC injection (typically 2-3 separate sites).
What is the reported half-life of Hulk Stack?
The reported half-life of Hulk Stack is CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs.
Is Hulk Stack FDA-approved?
No. Hulk Stack is not an FDA-approved drug. PeptideHelper.org catalog status: Compounding Restricted.
What level of evidence supports Hulk Stack?
The current evidence base for Hulk Stack is best characterised as: Anecdotal. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Hulk Stack?
Known concerns reported in the literature for Hulk Stack include: Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved. Always consult a qualified clinician before any human use.
Is there anyone who should not use Hulk Stack?
No formal contraindications are established for Hulk Stack, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved. Always consult a qualified clinician before any human use.
How does Hulk Stack work?
The mechanism of action reported for Hulk Stack in the literature: Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation..
What is Hulk Stack studied for?
Hulk Stack has been studied in the published literature for: Muscle accrual and recovery support through layered GH + IGF action; reported effects include improved recovery and lean-mass gain during dosing cycles. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Hulk Stack?
Hulk Stack is classified as: GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog. Also known as: Hulk blend; IGF-1 LR3 + CJC-1295 + Ipamorelin; anabolic GH/IGF stack.
Drug class
- GHRH peptides, see all peptides tagged GHRH.
- GHRP peptides, see all peptides tagged GHRP.
- GH-secretagogue peptides, see all peptides tagged GH-secretagogue.
- IGF-1 peptides, see all peptides tagged IGF-1.
Research focus area
All peptides studied for Growth Hormone Secretion, ranked by evidence tier and regulatory status.
Primary sources
- Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab 2006. PMID 16352683
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
- Tomas FM et al. Long-Arg3-IGF-I (LR3-IGF-I) restores muscle growth in rats. J Endocrinol 1996. PMID 8943755
- Note: The Hulk Stack is a community / vendor-marketed three-compound protocol with no published trial of the combination. Evidence is anecdotal; cited papers describe each component separately.
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…